Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Today
9:36 AM
Over a week ago
Jun 1, 4:05 PM
Feb 5, 7:08 AM
Jan 21, 7:12 AM
Dec 8, 4:36 PM
Dec 5, 11:01 AM
Dec 5, 10:56 AM
Oct 6, 7:24 AM
No more stories
Competitive Advantages
Proprietary SNA Platform: Exicure's core competitive advantage was its unique Spherical Nucleic Acid (SNA™) technology, a proprietary 3D structure that significantly improves drug delivery and cellular uptake of nucleic acid therapeutics.
Enhanced Cellular Uptake: The SNA structure facilitated superior cell penetration across various tissues, including the central nervous system, without the need for external transfection agents, enabling access to difficult-to-reach intracellular targets.
Improved Drug Stability: SNAs demonstrated enhanced stability against nuclease degradation in biological environments, leading to prolonged therapeutic effects and potentially reduced dosing frequency compared to traditional linear oligonucleotides.
Risks
Clinical Development Setbacks: Failure in ongoing or future clinical trials for their drug candidates could halt progress and significantly impact their viability.
Funding and Liquidity Challenges: Inability to secure sufficient capital to fund research, development, and operations could lead to insolvency or necessitate further asset sales.
Regulatory Approval Obstacles: Failure to obtain necessary regulatory approvals from agencies like the FDA for new drug candidates, even if trials are successful.
